Suppr超能文献

微小RNA-141的下调介导了对曲妥珠单抗的获得性耐药,并通过上调ERBB4的表达与乳腺癌的不良预后相关。

Downregulation of miroRNA-141 mediates acquired resistance to trastuzumab and is associated with poor outcome in breast cancer by upregulating the expression of ERBB4.

作者信息

Han Guodong, Qiu Ni, Luo Kai, Liang Hongling, Li Hongsheng

机构信息

Department of Breast Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong, P. R. China.

出版信息

J Cell Biochem. 2019 Jul;120(7):11390-11400. doi: 10.1002/jcb.28416. Epub 2019 Feb 11.

Abstract

BACKGROUND

microRNAs are involved in the control of cell growth and apoptosis; they also play an essential role in resistance towards trastuzumab, in breast cancer. The objective of this study was to identify differentially expressed microRNA(s) and explore its therapeutic role in treatment of the disease.

METHODS

Real-time polymerase chain reaction (RT-PCR) was performed to identify the virtual microRNA (miRNA) involved in breast cancer cells resistant to trastuzumab. RT-PCR and Western blot analysis were carried out to study the effects of microRNA-141 (miR-141) on ERBB2, ERBB4 and AKT production. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenylterazolium bromide assay and flow cytometry analysis was carried out to examine the effect of miR-141 on cell proliferation and apoptosis via ERBB4.

RESULT

According to RT-PCR results, only miR-141 and miR-375 among miR-141, miR-375, miR-16, miR-155, miR-217 and miR-205 were downregulated in trastuzumab-resistant cells. Trastuzumab-resistant cells displayed higher levels of ERBB4 and p-AKT as well as showing a higher growth rate and a lower apoptosis rate. Online software programs were used, which identified ERBB4 as a gene targeted by miR-141 with a highly conserved binding site for miR-141 located within the ERBB4 3'-untranslated region. In trastuzumab-resistant cells, miR-141 and shERBB4 reduced ERBB4 and p-AKT levels; ERBB2 and total AKT levels in miR-141 and shERBB4 groups showed no significant difference. Anti-miR-141 was upregulated ERBB4 and p-AKT levels in parental cell and had no obvious effect on ERBB2 and total AKT levels. Finally, miR-141 upregulated viability of the cells, which was restored by shERBB4, miR-141 and shERBB4 inhibited proliferation, and enhanced apoptosis of trastuzumab-resistant cells. miR-141 inhibitor caused an evident increase in proliferation and an obvious decrease in apoptosis of parental cells.

CONCLUSION

Knockdown of miR-141 causes overexpression of ERBB4, which is involved in trastuzumab resistance in breast cancer cells. This study has implications that miR-141 as well as its target, ERBB4, as a potential target for treating trastuzumab-resistant breast cancers.

摘要

背景

微小RNA参与细胞生长和凋亡的调控;它们在乳腺癌对曲妥珠单抗的耐药性中也起着至关重要的作用。本研究的目的是鉴定差异表达的微小RNA,并探讨其在该疾病治疗中的作用。

方法

采用实时聚合酶链反应(RT-PCR)鉴定参与曲妥珠单抗耐药的乳腺癌细胞中的微小RNA(miRNA)。进行RT-PCR和蛋白质免疫印迹分析以研究微小RNA-141(miR-141)对ERBB2、ERBB4和AKT表达的影响。采用3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐比色法和流式细胞术分析来检测miR-141通过ERBB4对细胞增殖和凋亡的影响。

结果

根据RT-PCR结果,在miR-141、miR-375、miR-16、miR-155、miR-217和miR-205中,只有miR-141和miR-375在曲妥珠单抗耐药细胞中表达下调。曲妥珠单抗耐药细胞中ERBB4和p-AKT水平较高,生长速率较高,凋亡率较低。使用在线软件程序,确定ERBB4是miR-141的靶基因,在ERBB4的3'-非翻译区内有一个高度保守的miR-141结合位点。在曲妥珠单抗耐药细胞中,miR-141和shERBB4降低了ERBB4和p-AKT水平;miR-141和shERBB4组中的ERBB2和总AKT水平无显著差异。抗miR-141上调了亲本细胞中ERBB4和p-AKT水平,对ERBB2和总AKT水平无明显影响。最后,miR-141上调了细胞活力,shERBB4可使其恢复,miR-141和shERBB4抑制了曲妥珠单抗耐药细胞的增殖并增强了其凋亡。miR-141抑制剂导致亲本细胞增殖明显增加,凋亡明显减少。

结论

敲低miR-141导致ERBB4过表达,这与乳腺癌细胞对曲妥珠单抗耐药有关。本研究表明,miR-141及其靶标ERBB4作为治疗曲妥珠单抗耐药乳腺癌的潜在靶点具有重要意义。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验